Research Topics
| John E GerichSummaryAffiliation: University of Rochester Country: USA Publications
| Collaborators
|
Detail Information
Publications
Clinical significance, pathogenesis, and management of postprandial hyperglycemiaJohn E Gerich
Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA
Arch Intern Med 163:1306-16. 2003..This review summarizes epidemiologic and experimental studies linking postprandial hyperglycemia to cardiovascular disease and therapeutic approaches available and in development to treat this disorder...- Mechanisms for abnormal postprandial glucose metabolism in type 2 diabetesHans J Woerle
Department of Medicine, University of Rochester School of Medicine, Rochester, NY 14642, USA
Am J Physiol Endocrinol Metab 290:E67-E77. 2006..g., liver and muscle) into other tissues... - Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimensHans J Woerle
Department of Medicine, University of Rochester School of Medicine, Rochester, New York, USA
Diabetes 52:918-25. 2003.... - Renal compensation for impaired hepatic glucose release during hypoglycemia in type 2 diabetes: further evidence for hepatorenal reciprocityHans J Woerle
Department of Medicine, University of Rochester School of Medicine, 601 Elmwood Avenue, Rochester, NY 14642, USA
Diabetes 52:1386-92. 2003.... - Abnormal renal, hepatic, and muscle glucose metabolism following glucose ingestion in type 2 diabetesChristian Meyer
Department of Medicine, University of Rochester School of Medicine, Rochester, NY 14642, USA
Am J Physiol Endocrinol Metab 287:E1049-56. 2004..The latter may provide an explanation for the renal glycogen accumulation characteristic of diabetes mellitus as well as a mechanism by which hyperglycemia may lead to diabetic nephropathy... - Effects of glimepiride and glyburide on glucose counterregulation and recovery from hypoglycemiaErvin Szoke
Department of Medicine, University of Rochester School of Medicine, Rochester, NY 14642, USA
Metabolism 55:78-83. 2006..This differential effect on insulin secretion may be an important factor in explaining why glyburide causes severe hypoglycemia more frequently than glimepiride... - Pathways for glucose disposal after meal ingestion in humansHans J Woerle
Department of Medicine, University of Rochester School of Medicine, Rochester, New York 14642, USA
Am J Physiol Endocrinol Metab 284:E716-25. 2003..The majority of glycogen is formed via the direct pathway ( approximately 73%)... - Effect of aging on glucose homeostasis: accelerated deterioration of beta-cell function in individuals with impaired glucose toleranceErvin Szoke
Department of Medicine, University of Rochester School of Medicine, Rochester, New York, USA
Diabetes Care 31:539-43. 2008..To examine the effect of aging on insulin secretion (first- and second-phase insulin release) and insulin sensitivity in people with normal glucose tolerance (NGT) or impaired glucose tolerance (IGT)... - Diagnostic and therapeutic implications of relationships between fasting, 2-hour postchallenge plasma glucose and hemoglobin a1c valuesHans J Woerle
Department of Medicine, University of Rochester School of Medicine, Rochester, NY 14642, USA
Arch Intern Med 164:1627-32. 2004..11 mmol/L) is too high and that attempts to lower HbA1c in these individuals will require treatment preferentially directed at lowering postprandial glucose levels... - Postprandial hyperglycemia and cardiovascular diseaseJohn E Gerich
Department of Medicine, University of Rochester, New York, USA
Endocr Pract 12:47-51. 2006..CONCLUSION: Postprandial hyperglycemia should be considered a cardiovascular risk factor similar to hypertension, hyperlipidemia, and smoking; accordingly, it should be monitored and treated... - Clinicians can help their patients control postprandial hyperglycemia as a means of reducing cardiovascular riskJohn E Gerich
General Clinical Research Center, University of Rochester, 601 Elmwood Avenue, Box MED CRC, Rochester, NY 14642, USA
Diabetes Educ 32:513-4, 520-2. 2006..Case studies are presented to aid clinicians in helping patients learn how to measure and control their postprandial glucose levels... 
Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)Vivian A Fonseca
Department of Medicine, Tulane University Health Sciences Center, New Orleans, Louisiana, USA
Diabetes Care 35:1225-31. 2012..To assess efficacy and safety of lixisenatide monotherapy in type 2 diabetes...
Is a history of gestational diabetes related to risk factors for coronary heart disease?Kathleen B King
University of Rochester School of Nursing, 601 Elmwood Avenue, Rochester, NY 14642, USA
Res Nurs Health 32:298-306. 2009..01. Two-hour post-load glucose indicated that 45% of hGDM cases were pre-diabetic versus 20% of controls, p < or = .05. Non-diabetic women with a distant hGDM are at increased risk for DM and may be at increased risk for CHD...- Role of impaired insulin secretion and insulin resistance in the pathogenesis of type 2 diabetes mellitusErvin Szoke
Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
Compr Ther 31:106-12. 2005..Targeting both insulin resistance and impaired insulin secretion is therefore appropriate to prevent T2DM and to improve glycemic control in those with the disorder... - Role of the kidney in hyperglycemia in type 2 diabetesChristian Meyer
Department of Medicine, University of Rochester School of Medicine, 601 Elmwood Avenue, Box MED/CRC, Rochester, NY 14642, USA
Curr Diab Rep 2:237-41. 2002.... - The rationale for paired pre- and postprandial self-monitoring of blood glucose: the role of glycemic variability in micro- and macrovascular riskJohn E Gerich
University of Rochester School of Medicine, Rochester, NY 14642, USA
Curr Med Res Opin 23:1791-8. 2007..Recent studies suggest that newer therapies specifically targeting postprandial hyperglycemia can significantly reduce postprandial glucose levels and improve overall glycemic control... - Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular riskAjikumar V Aryangat
University of Rochester, Rochester, New York 14642, USA
Vasc Health Risk Manag 6:145-55. 2010.... - Insulin glargine: long-acting basal insulin analog for improved metabolic controlJohn E Gerich
School of Medicine and Dentistry, University of Rochester, 601 Elmwood Avenue, Box MED CRC, Rochester, NY 14642, USA
Curr Med Res Opin 20:31-7. 2004..This review describes the unique pharmacokinetic properties and clinical efficacy of insulin glargine... - Novel insulins: expanding options in diabetes managementJohn E Gerich
Department of Medicine, Physiology, and Pharmacology, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
Am J Med 113:308-16. 2002..Other long-acting analogs, such as fatty acid acylated insulins, have been tested in animal models and are being evaluated in clinical studies... - Type 2 diabetes mellitus is associated with multiple cardiometabolic risk factorsJohn E Gerich
Endocrinology and Metabolism Unit, University of Rochester School of Medicine, Rochester, New York 14627, USA
Clin Cornerstone 8:53-68. 2007.... - The importance of tight glycemic controlJohn E Gerich
University of Rochester School of Medicine, Rochester, New York 14642, USA
Am J Med 118:7S-11S. 2005..Meal-related self-monitoring of blood glucose can inform patients and their healthcare providers about postprandial glycemic excursions so that diet, exercise, or medications can be adjusted... - Contributions of insulin-resistance and insulin-secretory defects to the pathogenesis of type 2 diabetes mellitusJohn E Gerich
Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
Mayo Clin Proc 78:447-56. 2003..Therefore, clinicians managing type 2 diabetes must reduce insulin resistance and augment and/or replace beta-cell function... - Is reduced first-phase insulin release the earliest detectable abnormality in individuals destined to develop type 2 diabetes?John E Gerich
Department of Medicine, University of Rochester, Rochester, NY, USA
Diabetes 51:S117-21. 2002.... - Advances in diabetes for the millennium: understanding insulin resistanceJohn E Gerich
Clinical Research Center, University of Rochester School of Medicine, Rochester, New York, USA
MedGenMed 6:11. 2004..Therefore, agents that improve beta-cell function (such as sulfonylureas and meglitinides) and insulin sensitizers (such as metformin and thiazolidinediones) both are useful alone or in combination for treating type 2 diabetes... - Role of human liver, kidney, and skeletal muscle in postprandial glucose homeostasisChristian Meyer
Department of Medicine, University of Rochester School of Medicine, Rochester, New York 14642, USA
Am J Physiol Endocrinol Metab 282:E419-27. 2002..We postulate that increases in postprandial renal glucose release may play a role in facilitating efficient liver glycogen repletion by permitting substantial suppression of hepatic glucose release... - Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes Importance of postprandial glycemia to achieve target HbA1c levelsHans J Woerle
Department of Internal Medicine II, Clinical Research Unit CRU, Ludwig Maximilian University Munich, Grosshadern Marchioninistr 15, Munich 81377, Germany
Diabetes Res Clin Pract 77:280-5. 2007..Cross-sectional studies suggest that attainment of HbA1c goals requires specific targeting of postprandial hyperglycemia... - The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implicationsBeth Elaine Dunning
PharmaWrite, Princeton, New Jersey 08540, USA
Endocr Rev 28:253-83. 2007.... - Disturbances in beta-cell function in impaired fasting glycemiaTimon W van Haeften
Department of Internal Medicine, University Medical Center Utrecht, Utrecht, The Netherlands
Diabetes 51:S265-70. 2002..05). We conclude that the early stages of glucose intolerance are associated with disturbances in beta-cell function, while insulin resistance is seen more markedly in later stages... - Increasing the decrement in insulin secretion improves glucagon responses to hypoglycemia in advanced type 2 diabetesZarmen Israelian
Department of Endocrinology, Carl T. Hayden VA Medical Center, Phoenix, AZ 85012, USA
Diabetes Care 28:2691-6. 2005..These findings further support the concept that the impaired counterregulatory glucagon responses in advanced beta-cell failure may at least partially be due to a reduced decrement in insulin secretion... - Autoregulation of endogenous glucose production during hyperglucagonemiaIngrid Toft
Institute of Clinical Medicine, University of Troms, Norway
Metabolism 51:1128-34. 2002..5 +/- 0.6 versus 11.6 +/- 0.6 micromol/kg/min (P =.19). We conclude that in normal volunteers, neither hyperglucagonemia nor the combination of hyperglucagonemia and increased substrate availability alters the autoregulation of EGP... - Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trialJay S Skyler
University of Miami, School of Medicine, Miami, FL 33136, USA
Diabetes Care 28:1630-5. 2005..We investigated whether a basal/bolus insulin regimen involving rapid-acting, dry powder, inhaled insulin could provide glycemic control comparable with a basal/bolus subcutaneous regimen... - Role of the decrement in intraislet insulin for the glucagon response to hypoglycemia in humansNiyaz R Gosmanov
Carl T Hayden VA Medical Center, 650 E Indian School Road, Phoenix, AZ 85012, USA
Diabetes Care 28:1124-31. 2005..However, in humans this role of decreased intraislet insulin is still unclear... - Multiple defects in counterregulation of hypoglycemia in modestly advanced type 2 diabetes mellitusZarmen Israelian
Department of Endocrinology, Carl T. Hayden VA Medical Center, Phoenix, AZ 85012, and Department of Medicine, University of Rochester School of Medicine, NY 14642, USA
Metabolism 55:593-8. 2006..These include delayed and reduced decreases in insulin secretion, and impaired increases of plasma glucagon and growth hormone...